{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:25:43Z","timestamp":1787109943631,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020684","name":"University of Calgary Arnie Charbonneau Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105480","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:00:18Z","timestamp":1783782018000},"page":"105480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical evidence for immune cell-based therapy for head and neck cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"225","author":[{"given":"Dong-Hyeon","family":"Jo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongbok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-4174","authenticated-orcid":false,"given":"Min-Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105480_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41467-025-56527-0","article-title":"Unlocking the potential of engineered immune cell therapy for solid tumors","volume":"16","author":"Albarr\u00e1n-Fern\u00e1ndez","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105480_bib2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105480_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.11124\/JBIES-22-00125","article-title":"Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.critrevonc.2026.105480_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705096","article-title":"Anti-PD-1 and Anti-PD-L1 in head and neck cancer: a network meta-analysis","volume":"12","author":"Botticelli","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib5","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105480_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.critrevonc.2026.105480_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hed.10195","article-title":"Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer","volume":"25","author":"Chang","year":"2003","journal-title":"Head. Neck"},{"key":"10.1016\/j.critrevonc.2026.105480_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105480_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105480_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib11","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105480_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356148","article-title":"The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis","volume":"6","author":"de Ruiter","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105480_bib14","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105480_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0330805","article-title":"Global burden of head and neck cancer from 1990 to 2021: a comprehensive analysis and projections to 2030 based on the global burden of disease study 2021","volume":"20","author":"Deng","year":"2025","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105480_bib16","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105480_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41368-021-00131-7","article-title":"Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma","volume":"13","author":"Elmusrati","year":"2021","journal-title":"Int. J. Oral. Sci."},{"key":"10.1016\/j.critrevonc.2026.105480_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CJI.0000000000000113","article-title":"Phase I clinical trial of 4-1BB-based adoptive T-cell therapy for Epstein-Barr virus (EBV)-positive tumors","volume":"39","author":"Eom","year":"2016","journal-title":"J. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105480_bib20","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","article-title":"Immunology and immunotherapy of head and neck cancer","volume":"33","author":"Ferris","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib21","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105480_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011633","article-title":"Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"13","author":"Ferris","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib23","unstructured":"Food, U.S., Drug, A., 2025. FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck. U.S. Food and Drug Administration, Silver Spring, MD."},{"key":"10.1016\/j.critrevonc.2026.105480_bib24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3389\/fonc.2020.00600","article-title":"Targeting Epstein-Barr virus in nasopharyngeal carcinoma","volume":"10","author":"Hau","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105480_bib27","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","article-title":"FDA approval summary: lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1-based immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105480_bib28","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/cncr.30541","article-title":"Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma","volume":"123","author":"Huang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib29","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105480_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66801-w","article-title":"Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial","volume":"16","author":"Iinuma","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105480_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.intimp.2015.05.042","article-title":"Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC","volume":"28","author":"Jiang","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib32","article-title":"Chemoradiotherapy combined with NK cell transfer in a patient with recurrent and metastatic nasopharyngeal carcinoma inducing long-term tumor control: a case report","volume":"99","author":"Jin","year":"2020","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.critrevonc.2026.105480_bib33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105480_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF01878078","article-title":"Locoregional immunotherapy of head and neck cancers utilizing allogeneic spleen cells: a report of 2 cases","volume":"6","author":"Kubota","year":"1993","journal-title":"Biotherapy"},{"key":"10.1016\/j.critrevonc.2026.105480_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1010-5182(05)80529-3","article-title":"Tumoricidal effect of human PBMC following stimulation with OK-432 and its application for locoregional immunotherapy in head and neck cancer patients","volume":"21","author":"Kubota","year":"1993","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.critrevonc.2026.105480_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib37","doi-asserted-by":"crossref","DOI":"10.4161\/23723556.2014.976507","article-title":"Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"4","author":"Li","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105480_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CJI.0b013e318241d9de","article-title":"Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma","volume":"35","author":"Li","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105480_bib39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molmed.2025.05.014","article-title":"IL-15 in CAR engineering: striking an efficacy-safety balance","volume":"31","author":"Li","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105480_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112965","article-title":"A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein\u2013Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients","volume":"191","author":"Liang","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib41","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s00262-022-03158-9","article-title":"Phase I study of expanded natural killer cells in combination with cetuximab for recurrent\/metastatic nasopharyngeal carcinoma","volume":"71","author":"Lim","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105480_bib42","first-page":"6952","article-title":"Immunization with Epstein\u2013Barr virus peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with Epstein\u2013Barr virus-positive nasopharyngeal carcinoma","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105480_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","volume":"22","author":"Lopez de Rodas","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib44","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood-2008-05-157222","article-title":"Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients","volume":"113","author":"Louis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105480_bib45","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105480_bib46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1128\/CVI.00121-13","article-title":"Cytotoxic T-cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma","volume":"21","author":"Lutzky","year":"2014","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007573","article-title":"Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites","volume":"12","author":"Muijlwijk","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib48","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.critrevonc.2026.105480_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib50","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3892\/ijo.2014.2599","article-title":"Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers","volume":"45","author":"Ohtani","year":"2014","journal-title":"Int. J. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2026.105480_bib51","first-page":"A523","article-title":"Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-na\u00efve patients with advanced cancers","volume":"9","author":"O'Malley","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib52","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105480_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007162","article-title":"Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study","volume":"11","author":"Papa","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105480_bib54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00262-007-0283-6","article-title":"Adoptive therapy of head and neck squamous cell carcinoma with antibody-coated immune cells: a pilot clinical trial","volume":"56","author":"Riechelmann","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105480_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40364-025-00783-1","article-title":"Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma","volume":"13","author":"Saeidpour Masouleh","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105480_bib56","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1208475","article-title":"Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma","volume":"14","author":"Secondino","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/annonc\/mdr134","article-title":"T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results","volume":"23","author":"Secondino","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib59","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01669-3","article-title":"First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer","volume":"18","author":"Shapiro","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib61","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamaoto.2024.5254","article-title":"Current progress and future directions of immunotherapy in head and neck squamous cell carcinoma: a narrative review","volume":"151","author":"Sim","year":"2025","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.critrevonc.2026.105480_bib62","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1016\/j.ymthe.2024.09.015","article-title":"Approval of the first TCR-based cell therapy","volume":"32","author":"Singh","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105480_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1273311","article-title":"Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of T cells impact on clinical response","volume":"6","author":"Smith","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105480_bib64","article-title":"Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma","volume":"5","author":"Smith","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib65","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","article-title":"Effective treatment of metastatic forms of Epstein\u2013Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy","volume":"72","author":"Smith","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105480_bib66","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/030089169007600611","article-title":"Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2","volume":"76","author":"Squadrelli-Saraceno","year":"1990","journal-title":"Tumori"},{"key":"10.1016\/j.critrevonc.2026.105480_bib67","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105480_bib68","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105480_bib69","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105480_bib70","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105480_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2026.105480_bib72","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/archotol.126.10.1225","article-title":"Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study","volume":"126","author":"To","year":"2000","journal-title":"Arch. Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.critrevonc.2026.105480_bib73","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.annonc.2024.08.2344","article-title":"Gemcitabine, carboplatin, and Epstein\u2013Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial","volume":"35","author":"Toh","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117544","article-title":"The prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: a systematic review and meta-analysis","volume":"180","author":"Torri","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105480_bib75","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/2326-6066.CIR-22-0444","article-title":"Feasibility and safety of personalized, multi-target, adoptive cell therapy (IMA101): first-in-human clinical trial in patients with advanced metastatic cancer","volume":"11","author":"Tsimberidou","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105480_bib76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-007-0373-5","article-title":"Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer","volume":"57","author":"Uchida","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105480_bib77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105480_bib78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clim.2010.11.014","article-title":"Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy","volume":"138","author":"Yamasaki","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106786","article-title":"Efficacy and safety of cell-based immunotherapy in the treatment of recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"152","author":"Yeo","year":"2024","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41571-024-00969-w","article-title":"T cell dynamics with neoadjuvant immunotherapy in head and neck cancer","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105480_bib81","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal. Transduct. Target. Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:39:35Z","timestamp":1787107175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":81,"alternative-id":["S1040842826003677"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105480","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical evidence for immune cell-based therapy for head and neck cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105480"}}